Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

OKs

Step Challenge for Oscars Kids!

April 25th 2023

Read More

Banner

Shorla Oncology will be attending Asembia’s ASX Summit in Las Vegas

April 17th 2023

Read More

Oncology Live Logo

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

July 18th 2025March 27th 2023

Read More

Banner

Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023

March 23rd 2023

Read More

Logo

US FDA approves Shorla’s oncology drug for T-cell leukaemia

March 20th 2023

Read More

Logo

Shorla wins FDA approval for leukaemia drug

March 20th 2023

Read More

Logo

Irish-founded Shorla Oncology secures FDA approval for leukaemia drug

March 9th 2023

Read More

Banner

Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia

March 9th 2023

Read More

Banner

We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently!

January 16th 2023

Read More

Older posts
Newer posts
Page1 … Page10 Page11 Page12 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.